Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Wednesday 22 January, 2020

T.Rowe Price Assoc

Form 8.3 - [AbbVie Inc]

RNS Number : 6250A
T.Rowe Price Associates
22 January 2020
 

Ap19

 

FORM 8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.       KEY INFORMATION

 

Name of person dealing (Note 1)

 T. ROWE PRICE ASSOCIATES, INC.

Company dealt in

 ABBVIE INC

Class of relevant security to which the dealings being disclosed relate (Note 2)

 ISIN:

Date of dealing

 21 January 2020

2.         INTERESTS AND SHORT POSITIONS

 

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

 

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 31,587,011            2.13%

 

(2) Derivatives (other than options)

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 31,587,011            2.13%

 

             

 

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:

Long

Short

 

Number

 

(%)

Number

 

(%)

(1) Relevant securities

 

 

 

(2) Derivatives (other than options)

 

 

 

(3) Options and agreements to purchase/sell

 

 

Total

 

 

             

 

Ap20

 

 

1.       DEALINGS (Note 4)

 

(a)      Purchases and sales

 

 

Purchase/sale

 

Number of relevant securities

 

Price per unit (Note 5)

Purchases

 

 

 

 

 

 

 

 

 

Sale

 

 

 

 

 

 

 

 

 

 

 

 

864

99,520

100

9

11

400

3,044,367

157,424

33,400

41,097

1,284

 

 

 

 

87.990 USD

88.000 USD

88.050 USD

88.060 USD

88.090 USD

88.115 USD

88.135 USD

88.152 USD

88.180 USD

88.269 USD

87.990 USD

 

(b)      Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 6)

Number of relevant securities

(Note 7)

Price per unit

(Note 5)

 

 

 

 

 

(c)      Options transactions in respect of existing relevant securities

 

 

(i)       Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 5)

 

 

 

 

 

 

 

 

(ii)      Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 5)

 

 

 

 

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

 

2.       OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and 

any other person relating to the voting rights of any relevant securities under any option referred to 

on this form or relating to the voting rights or future acquisition or disposal of any relevant securities 

to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached? (Note 9)                                            YES/NO

 

Date of disclosure

 22 January 2020

Contact name

 Gary Greb

Telephone number

 001 410 345 2527

If a connected EFM, name of offeree/offeror with which connected

 

If a connected EFM, state nature of connection (Note 10)

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEKKBBDQBKDQDB

a d v e r t i s e m e n t